We choose patients mostly with no evident disease activity because we try to find a difference in LAIR1 expression and function between healthy individuals and SLE affected patients, avoiding the contribution of other elements due to the flare of the illness and therapy. The gene discussed is LAIR1; the disease is systemic lupus erythematosus.